MODUS Multi-Organ Denervation Study

About Metavention

Metavention is a private, pre-revenue biotech company founded in 2010 and headquartered in Minneapolis, USA. It is advancing a catheter-based radiofrequency denervation platform targeting the sympathetic nervous system to treat hypertension and type 2 diabetes. The company is currently conducting multiple early-stage clinical studies (DeLIVER and MODUS) in the U.S., Australia, and New Zealand to evaluate the safety and performance of its iRF Denervation System for both renal and hepatic nerve ablation.

Therapeutic Areas